Merck (NYSE:MRK) reported positive results from late-stage studies on a new oral treatment which combines two drugs, doravirine and islatravir, for adults with HIV-1. The studies looked at adults whose HIV was under control using another treatment called bictegravir/emtricitabine/tenofovir alafenamide ...